A study to test how different doses of BI 3814916 are tolerated by healthy people

2025-523262-25-00 Protocol 1543-0001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 11 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 1543-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 136
Countries 1
Sites 1

healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
11 May 2026 → ongoing
Decision date (initial)
2026-03-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-523262-25-00
WHO UTN
U1111-1325-7389

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 136 1
Rest of world 0

Investigational sites

Belgium

1 site · Ongoing, recruiting
SGS Belgium
Clinical Pharmacology Unit, Drie Eikenstraat 655, 2650, Edegem

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2026-05-11 2026-05-20

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-28 Belgium Acceptable with conditions
2026-03-13
2026-03-13
2 SUBSTANTIAL MODIFICATION SM-1 2026-04-02 Belgium Acceptable
2026-05-11
2026-05-11